We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.05 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 530k | -5.41M | -0.0946 | -0.32 | 1.74M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 3.05 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 20/3/2024 | 18:11 | ALNC |  TRADING UPDATES: ReNeuron appoints administrators as rescue talks fail |
| 20/3/2024 | 15:43 | UK RNS | ReNeuron Group plc Appointment of Administrators |
| 20/3/2024 | 12:30 | UK RNS | ReNeuron Group plc Intention to Appoint Administrators |
| 01/3/2024 | 07:00 | UK RNS | ReNeuron Group plc Block Listing Review & Total Voting Rights |
| 05/2/2024 | 20:23 | ALNC | TRADING UPDATES: ReNeuron warns; Gama Aviation pledges cash return |
| 05/2/2024 | 14:42 | ALNC | *ReNeuron requests suspension of shares |
| 05/2/2024 | 14:30 | UK RNS | ReNeuron Group plc Corporate update and suspension of trading on AIM |
| 05/2/2024 | 14:30 | UK RNS | AIM Suspension - ReNeuron Group plc |
| 08/11/2023 | 12:21 | ALNC | ReNeuron interim loss narrows on lower costs; eyes partnerships |
| 08/11/2023 | 07:01 | UKREG | ReNeuron Group plc Interim Results for the six months ended 30 Sept |
Reneuron (RENE) Share Charts1 Year Reneuron Chart |
|
1 Month Reneuron Chart |
Intraday Reneuron Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 21/3/2024 | 10:36 | ReNeuron - a leading, clinical-stage stem cell business | 8,623 |
| 20/3/2024 | 14:22 | Rene on the road to recovery. You have been warned BUY BUY BUY switch is on | 251 |
| 28/10/2021 | 11:40 | Interesting article...albeit lengthly | 6 |
| 10/6/2021 | 10:30 | New Chief Scientific Officer | 2 |
| 17/10/2019 | 15:33 | RENE - No revenues, no approvals, rising salaries and loads of dilution | 8 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 15/4/2024 09:20 by Reneuron Daily Update Reneuron Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 3.05p.Reneuron currently has 57,173,760 shares in issue. The market capitalisation of Reneuron is £1,743,800. Reneuron has a price to earnings ratio (PE ratio) of -0.32. This morning RENE shares opened at - |
Posted at 20/3/2024 13:03 by luckyabbeygale Just googled it and it can take up to a year for this process. Therefore Rene will continue to show its last trading price for up to a year and then the delisting will happen. |
Posted at 14/3/2024 15:27 by luckyabbeygale I still hoping the last price counts for spread bets on limited risk. As it will be against the law for them to go to 0.As its like ig index have issued a debt against me that will be taken out of my Oriole position. If they do take it out I will be going straight to the FCA since I will be seeking compensation. |
Posted at 06/2/2024 11:54 by luckyabbeygale Thankyou. My Redrock was up about 3 grand. I am tempted to just let it all ride for the result of the court case. As if they win the reward maybe my highest ever gain that I have made on a share.I do wonder if spreadbets get any benefit if Rene go bust and end up going up 500% as a cash shell. |
Posted at 06/2/2024 11:19 by luckyabbeygale In hindsight I should of escaped from my cfd account future losses on Rene by putting it all into redrock during the time I topped up on redrock at 0.095p using some share deal funds. As redrock is in a court case for 8.5m and if they win they will use that money to fight glencore for 200m after fees. |
Posted at 06/2/2024 07:43 by luckyabbeygale It was always fusion antibodies the one with all the cash. I have 7 grand in them. This Rene loss delay is at least letting me build my pot back up. |
Posted at 05/2/2024 15:19 by waterloo01 waterloo01 - 18 Jan 2022 - 07:35:32 - 8236 of 8586ReNeuron - a leading, clinical-stage stem cell business - RENEAs an ex old holder, sorry to see the RP data. It was kind of clear from earlier data that it was problematic. Terminator101 not far from the truth of it unfortunately, |
Posted at 05/2/2024 14:59 by luckyabbeygale If I closed all my positions on the other stocks I then not have any loss from Rene. However I can not do that since I am in too deep on them all. |
Posted at 05/2/2024 14:33 by tomboyb 5 February 2024ReNeuron Group plc ("ReNeuron", the "Group" or the "Company") Corporate update and suspension of trading on AIM ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, provides the following update in relation to its current business development, financing discussions and working capital position. On 8 November 2023, the Group announced its Interim Results for the six months ended 30 September 2023 ("Interim Results"). At the time, the Board stated that the outlook for the business remained positive provided it could retain its' highly dedicated team of scientists, further develop and verify the CustomEX™ exosome delivery platform and conclude validating industry partnerships. As also announced in the Interim Results, potential corporate actions that were under consideration by the Board included raising additional equity financing and/or securing a financing facility and/or entering into M&A discussions. The Group also noted in the Interim Results that as at 30 September 2023, the Group had cash, cash equivalents and bank deposits of £5.1 million and that the Group's latest internal projections (assuming no new revenues or funding) meant there was a cash runway to April 2024, ahead of which point further revenues and/or a capital injection would be required. In the intervening period, despite great scientific progress having been made in further developing and exemplifying the CustomEX™ exosome delivery platform and progressing several ongoing third-party business development discussions, the Group has not yet been able to conclude a validating, revenue generating industry partnership nor been able to secure additional equity funding. Accordingly, throughout the period the Group has been carefully managing its working capital, but it is now in a highly constrained financial position and requires additional financing urgently, in order to continue as a going concern. In the absence of any additional financing being available in the immediate term, the Group now needs to take steps to preserve and maximise value for its creditors. Whilst the Group continues to explore a number of corporate options, including seeking to realise value for its physical and intellectual assets, the Board recognises that in the absence of an immediate injection of capital and in view of the current financial uncertainty, it needs to put staff at risk of redundancy, initiate discussions with its creditors and establish the precise solvency status of the business. Should the Company fail to achieve a solution in the short term, the Board would have no option but to place the Company into administration. Should administrators be appointed, it is not known how much, if any, value would be returned to shareholders. In light of the above, the Company has requested a suspension of trading in its ordinary shares on AIM pending clarification of its financial position. Trading in the Company's ordinary shares has been suspended at 2:30 p.m. today and further updates will be provided in due course. Enquiries: |
Posted at 01/9/2023 15:09 by thiopia RENE ReneuronShare Price : 9.25p Shares o/s : 57.17m Mkt Cap : £5.3m Annual Report (y/e Mar 2023) "Cash, cash equivalents and bank deposits at 31 March 2023 of £7.2 million" " Executive Chairman, Iain Ross, commented: “ I remain very excited about the Company’s potential as we are on course to generate validating data which would allow us to complete partnering and license deals in the coming year which will transform the Company.” Data due September/October ( In vivo studies to generate data to further validate the cellular and tissue targeting capabilities and subsequent functional delivery of therapeutic payloads using the CustomEXTM platform are ongoing. Favourable in vivo data will allow the Group to differentiate its exosome platform and progress ongoing partnering and licensing discussions. The Board has identified a number of potential sources of revenue and non-dilutive funding in order to maintain the business as a going concern and is confident it will be able to conclude third party transactions and/or issue new equity as required. Such transactions will further strengthen and differentiate our exosomes platform, highlighting our potential leadership in the field. Technology Overview ReNeuron’s stem cell derived proprietary exosome technology platform CustomEX™ offers a delivery mechanism for a variety of potential payloads that could include siRNA, mRNA, proteins, small molecules and genes. What are exosomes? l Naturally occurring biological nano particles produced by every cell to mediate intercellular communication. l Can encapsulate various biological molecules within their lipid bilayer membrane or within the lumen of the Exosome. l Can be engineered to deliver drug cargos to target cells, offering an opportunity to treat diseases. The benefits of exosomes l Proven ability to carry and deliver a variety of cargos including proteins and nucleic acids. l Potential to deliver more than one bio-active cargo simultaneously. l Target recipient cells via specific surface proteins that are determined by their cell of origin. l Low or no immunogenicity, thereby evading immune detection. Current delivery mechanisms have limitations l Viral vectors have been plagued by side effect issues and high costs, limitation on the type and size of cargo they can deliver. l Lipid nanoparticles (LNPs) have no natural tissue and cell targeting capabilities with delivery therefore untargeted and mainly to the liver. l Both have immunogenetic properties that can be problematic. CustomExTM: A customisable exosome platform l Seven proprietary conditionally immortalised* exosome producer stem cell lines producing unique exosome populations. l ReNeuron’s iPSC platform allows production of exosomes that have the functional properties based on parent stem cells. l Capable of delivering a variety of payloads including proteins and nucleic acids and the next generation for delivery of gene editing technologies. l Data highlights increased uptake and delivery of payload when compared to a conventional HEK exosome approach. l Our CustomExTM exosomes have distinct surface marker profiles (tropisms) enabling a greater tissue targeting capability. *Conditional immortalisation of stem cell exosome producer lines offers an elegant solution to not only consistently produce cell lines that are genetically stable and can be grown at scale, but also to produce a high yielding source of consistent exosomes for the delivery of complex drug modalities. The standard approach used by our competitors is to produce exosomes from a single generic cell line. A one-size-fits-all approach. A single cell line, giving rise to a single outcome. CSO Randolph Corteling delivering Seminar Presentation in Boston due September 6th |
Posted at 20/8/2023 00:02 by thiopia ("ReNeuron" or the "Company")Notice of Annual General Meeting ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell derived exosome technologies , announces that the Notice of Annual General Meeting ("AGM") and Form of Proxy have today been posted to shareholders and will shortly be available on the investors section of the Company's website here . The AGM will be held at the offices of Covington & Burling LLP, Level 54, 22 Bishopsgate, London EC2N 4BQ on 22 August 2023 at 9.30 a.m. The Board welcomes the opportunity to invite shareholders to attend the AGM in person. Persons intending to attend and vote at the meeting in person will need a QR code to access the meeting venue. Such QR code will need to be displayed on a smartphone or similar device. A QR code will be able to be obtained in advance by emailing externalproxyqueries If shareholders are unable to attend the meeting in person, then they are encouraged to submit their votes by proxy by appointing the Chairman of the AGM as their proxy, so that their votes can be taken into account. Shareholders are also encouraged to submit any questions for the Chairman to info@reneuron.com at least 48 hours prior to the Meeting. Shareholders that are able to attend the AGM in person will also have an opportunity to ask questions at the Meeting. Where appropriate, questions and answers will be collated and later published on the Company's website at www.reneuron.com. The results of the proposed resolutions will be published on the Company website and announced via RNS as soon as practicable after the conclusion of the AGM. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
